Tuesday , October 24 2017
Home / Resources / Articles / Hypoglycemia Prevented by New Insulin

Hypoglycemia Prevented by New Insulin

An experimental insulin drug prevented low blood sugar among diabetic patients more often than insulins now available….

While treatment with insulin can help control blood sugar, it sometimes leads to abnormally low levels, or hypoglycemia. Symptoms of low blood sugar include headaches, tremors, and even seizures, so it is critical to develop medications that control blood sugar without causing extreme drops.

Lead investigator Daniel Einhorn, M.D., medical director at Scripps Whittier Diabetes Institute, and clinical professor of medicine at the University of California San Diego, mentioned in his presentation that, “Diabetes is an increasingly common disease, and many patients fail to achieve their treatment goals due to a fear of hypoglycemia.” “This puts them at risk of developing diabetes complications.”

While both medications in this large-scale analysis decreased blood-sugar concentrations, the experimental drug, degludec, caused fewer incidents of low blood sugar, especially at night-time, compared to glargine. Overall, low blood-sugar levels occurred 14 percent less often among degludec patients than among those receiving glargine. At night, low blood sugar occurred 37 percent less often among degludec than glargine recipients.

Sixteen weeks after the study, degludec patients had even fewer incidents of low blood sugar. During this maintenance period, the condition occurred 21 percent less frequently, overall, and 43 percent less often at night. No major complications were reported.

Einhorn said that, “This study suggests that blood glucose can be effectively lowered by degludec, with a lower risk for hypoglycemia compared to currently available insulins.” “It is therefore possible that treatment with degludec can improve patient outcomes by limiting the side effects associated with insulin use.”

Investigators analyzed data from seven separate clinical trials. Two of these trials focused on type 1 diabetes and the other five trials examined the most common form of diabetes, known as type 2, in which the body both responds inadequately to insulin and produces inadequate amounts of the hormone.

More than 3,000 participants were randomly assigned to receive either degludec or glargine once a day for 26 or 52 weeks. Of the total number, 2,899 patients received degludec, and 1,431 were given glargine. Nearly half of all patients on both drugs achieved targeted levels of blood-sugar control.

The study results were presented at The Endocrine Society’s 94th Annual Meeting in Houston, June 2012.